Is there hope for chronic pain and headache?

Headache

Volumn 47, Issue 8, 2007, Pages 1262-1271

  Romero Reyes, Marcela ^a   Graff Radford, Steven ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Central sensitization; Chronic pain; Glia; Headache; Neuropathic pain; Peripheral sensitization

Indexed keywords

AMITRIPTYLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CARBAMAZEPINE; FLUNARIZINE; GABAPENTIN; MEMENTINE; METHADONE; METHYSERGIDE; METOPROLOL; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; OXCARBAZEPINE; PREGABALIN; PROPRANOLOL; SODIUM CHANNEL BLOCKING AGENT; TONABERSAT; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL;

ACUPUNCTURE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLUSTER HEADACHE; DIABETIC NEUROPATHY; DRUG INDUCED HEADACHE; GENE MUTATION; GENETICS; HEADACHE; HUMAN; HYPERALGESIA; IMMUNE SYSTEM; MIGRAINE; MYOFASCIAL PAIN; NERVE CELL; NEUROPHYSIOLOGY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PHONOPHOBIA; PHOTOPHOBIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SURVIVAL; TOOTH PAIN; TRIGEMINUS NEURALGIA;

CHRONIC DISEASE; HEADACHE; HUMANS; PAIN;

EID: 34748901756     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00909.x     Document Type: Review

References (157)

1. Berkovitch M, Copeliovitch L, Tauber T, Vaknin Z, Lahat E. Hereditary insensitivity to pain with anhidrosis. Pediatr Neurol. 1998 19 (3 227 229.
2. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006 444 (7121 894 898.
3. Loder E. What is the evolutionary advantage of migraine? Cephalalgia. 2002 22 (8 624 632.
4. Kumazawa T. Primitivism and plasticity of pain-implication of polymodal receptors. Neuroscience Research. 1998 32 (1 9 31.
5. Basbaum AI, Woolf CJ. Pain. Curr Biol. 1999 9 (12 R429 R431.
6. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001 413 (6852 203 210.
7. Schmidt R, Schmelz M, Forster C, Ringkamp M, Torebjork E, Handwerker H. Novel classes of responsive and unresponsive C nociceptors in human skin. J Neurosci. 1995 15 (1 Pt 1 333 341.
8. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: New players in pain. Pain. 2001 93 (3 201 5.
9. Watkins LR, Milligan ED, Maier SF. Glial activation: A driving force for pathological pain. Trends Neurosci. 2001 24 (8 450 455.
10. Wang H, Ehnert C, Brenner GJ, Woolf CJ. Bradykinin and peripheral sensitization. Biol Chem. 2006 387 (1 11 14.
11. Boddeke EW. Involvement of chemokines in pain. Eur J Pharmacol. 2001 429 (1-3 115 119.
12. Merrill RL. Central mechanisms of orofacial pain. Dent Clin North Am. 2007 51 (1 45 59, v.
13. Fields HL, Levine JD. Pain-mechanics and management. West J Med. 1984 141 (3 347 357.
14. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002 5 (Suppl 1062 1067.
15. Merrill RL. Orofacial pain mechanisms and their clinical application. Dent Clin North Am. 1997 41 (2 167 188.
16. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: Implications for the initiation and maintenance of pathological pain. Neurobiol Dis. 2001 8 (1 1 10.
17. Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain. 2006 7 (1, Supplement 1 S13.
18. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science. 2000 288 (5472 1765 1769.
19. Bereiter DA, Hirata H, Hu JW. Trigeminal subnucleus caudalis: Beyond homologies with the spinal dorsal horn. Pain. 2000 88 (3 221 224.
20. Graff-Radford SB. Regional myofascial pain syndrome and headache: Principles of diagnosis and management. Curr Pain Headache Rep. 2001 5 (4 376 381.
21. Clark GT. Persistent orodental pain, atypical odontalgia, and phantom tooth pain: When are they neuropathic disorders? J Calif Dent Assoc. 2006 34 (8 599 609.
22. Zhu CZ, Wilson SG, Mikusa JP, et al. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol. 2004 506 (2 107 118.
23. Bordi F, Ugolini A. Group I metabotropic glutamate receptors: Implications for brain diseases. Prog Neurobiol. 1999 59 (1 55 79.
24. Dubner R. Three decades of pain research and its control. J Dent Res. 1997 76 (3 730 733.
25. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-Methyl-D-Aspartate (NMDA) receptors in pain: A review. Anesth Analg. 2003 97 (4 1108 1116.
26. Thompson SW, Urban L, Dray A. Contribution of NK1 and NK2 receptor activation to high threshold afferent fibre evoked ventral root responses in the rat spinal cord in vitro. Brain Res. 1993 625 (1 100 108.
27. Wu J, Fang L, Lin Q, Willis WD. Nitric oxide synthase in spinal cord central sensitization following intradermal injection of capsaicin. Pain. 2001 94 (1 47 58.
28. Watkins LR, Maier SF. Immune regulation of central nervous system functions: From sickness responses to pathological pain. J Intern Med. 2005 257 (2 139 155.
29. Xie YF, Zhang S, Chiang CY, Hu JW, Dostrovsky JO, Sessle BJ. Involvement of glia in central sensitization in trigeminal subnucleus caudalis (medullary dorsal horn). Brain Behav Immun. 2007 21 : 634 641.
30. Watkins LR. Immune and glial regulation of pain. Brain Behav Immun. 2007 21 : 519 521.
31. Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: Physiological and pathological consequences. Brain Behav Immun. 2005 19 (2 104 111.
32. Charles AC. Glia-neuron intercellular calcium signaling. Dev Neurosci. 1994 16 : 196 206.
33. Trang T, Beggs S, Salter MW. Purinoceptors in microglia and neuropathic pain. Pflugers Arch. 2006 452 (5 645 652.
34. Inoue K. The function of microglia through purinergic receptors: Neuropathic pain and cytokine release. Pharmacol Ther. 2006 109 (1-2 210 226.
35. Hansson E, Ronnback L. Glial neuronal signaling in the central nervous system. Faseb J. 2003 17 (3 341 348.
36. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001 65 (1 1 105.
37. Innocenti B, Parpura V, Haydon PG. Imaging extracellular waves of glutamate during calcium signaling in cultured astrocytes. J Neurosci. 2000 20 (5 1800 1808.
38. Zonta M, Sebelin A, Gobbo S, Fellin T, Pozzan T, Carmignoto G. Glutamate-mediated cytosolic calcium oscillations regulate a pulsatile prostaglandin release from cultured rat astrocytes. J Physiol. 2003 553 (Pt 2 407 414.
39. Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, Deleo JA. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun. 2007 21 (2 238 246.
40. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. NeuroImage. 2007 Epub ahead of print JC, Belfrage M, Stone-Elander S, Hansson P, Ingvar M. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. Pain. 1995 63 (2 225 236.
41. Kupers RC, Gybels JM, Gjedde A. Positron emission tomography study of a chronic pain patient successfully treated with somatosensory thalamic stimulation. Pain. 2000 87 (3 295 302.
42. Peyron R, Faillenot I, Mertens P, Laurent B, Garcia-Larrea L. Motor cortex stimulation in neuropathic pain. Correlations between analgesic effect and hemodynamic changes in the brain. A PET study. Neuroimage. 2007 34 (1 310 321.
43. Jones AK, Watabe H, Cunningham VJ, Jones T. Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET. Eur J Pain. 2004 8 (5 479 485.
44. Maarrawi J, Peyron R, Mertens P, et al. Differential brain opioid receptor availability in central and peripheral neuropathic pain. Pain. 2007 127 (1-2 183 194.
45. Goadsby PJ. Headache: a good year for research. Lancet Neurol. 2006 5 (1 5 6.
46. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin. 2001 17 (Suppl 1 s4-12.
47. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 (5 343 349.
48. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002 346 (4 257 270.
49. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004 24 (Suppl 2 2 7.
50. Durham PL. CGRP receptor antagonists: A new choice for acute treatment of migraine? Curr Opin Investig Drugs. 2004 5 (7 731 735.
51. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006 46 (Suppl 1 S3 8.
52. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000 15 (Suppl 3 28 35.
53. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000 47 (5 614 624.
54. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, et al. Wolff award: Possible parasympathetic contributions to peripheral and central sensitization during migraine. Headache. 2003 43 (7 704 714.
55. Shibata K, Yamane K, Iwata M. Change of excitability in brainstem and cortical visual processing in migraine exhibiting allodynia. Headache. 2006 46 (10 1535 1544.
56. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004 55 (1 19 26.
57. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999 26 (Suppl 3 S12 19.
58. Yamamura H, Malick A, Chamberlin NL, Burstein R. Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol. 1999 81 (2 479 493.
59. Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol. 2005 62 (8 1270 1275.
60. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005 128 (Pt 4 932 939.
61. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000 13 (3 277 283.
62. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001 5 (6 529 536.
63. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003 43 (4 336 42.
64. Goadsby PJ, Cohen AS, Matharu MS. Trigeminal autonomic cephalalgias: Diagnosis and treatment. Curr Neurol Neurosci Rep. 2007 7 (2 117 125.
65. Goadsby PJ, May A. PET demonstration of hypothalamic activation in cluster headache. Neurology. 1999 52 (7 1522.
66. May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet. 1998 352 (9124 275 278.
67. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995 1 (7 658 660.
68. Leone M, Proietti Cecchini A, Mea E, et al. Functional neuroimaging and headache pathophysiology: New findings and new prospects. Neurol Sci. 2007 28 (0 S108.
69. Silberstein SD, Niknam R, Rozen TD, Young WB. Cluster headache with aura. Neurology. 2000 54 (1 219 221.
70. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004 24 (Suppl 1 9 160.
71. Mathew NT. Chronic refractory headache. Neurology. 1993 43 (6 Suppl 3 S26 33.
72. Rothrock JF. Topiramate for chronic migraine. JHead Face Pain. 2007 47 (1 139.
73. Silberstein SD. Topiramate in migraine prevention: Evidence-based medicine from clinical trials. Neurol Sci. 2004 25 (Suppl 3 S244 5.
74. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache. 2007 47 (1 13 21.
75. Obermann M, Bartsch T, Katsarava Z. Medication overuse headache. Expert Opinion Drug Saf. 2006 5 (1 49 56.
76. Peeters M, Gunthorpe MJ, Strijbos PJLM, Goldsmith P, Upton N, James MF. Effects of pan- and subtype-selective NMDA receptor antagonists on cortical spreading depression in the rat: Therapeutic potential for migraine. J Pharmacol Exp Ther. 2007 321 : 564 572.
77. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol. 2006 6 (1 68.
78. Liverton NJ, Bednar RA, Bednar B, et al. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino) methyl]piperidine-1- carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist. J Med Chem. 2007 50 (4 807 819.
79. Oshinsky ML, Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 2006 46 (Suppl 1 S39 44.
80. Lee I, Kim HK, Kim JH, Chung K, Chung JM. The role of reactive oxygen species in capsaicin-induced mechanical hyperalgesia and in the activities of dorsal horn neurons. Pain 2007 Epub ahead of print J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994 15 (5 149 153.
81. Rejdak K, Empl M, Giffin NJ, et al. Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients. Eur J Neurol. 2006 13 (12 1346 1351.
82. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet. 1997 349 (9049 401.
83. Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol. 2002 51 (4 507 516.
84. Ledeboer A, Gamanos M, Lai W, et al. Involvement of spinal cord nuclear factor-kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur J Neurosci. 2005 22 (8 1977 1986.
85. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988 23 (2 193 196.
86. Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999 19 (9 3423 3429.
87. Fabbretti E, D'Arco M, Fabbro A, Simonetti M, Nistri A, Giniatullin R. Delayed upregulation of ATP P2'3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci. 2006 26 (23 6163 6171.
88. Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994 14 (5 320 327.
89. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 33 (1 48 56.
90. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia. 1995 15 (4 277 280.
91. Bellamy J, Bowen EJ, Russo AF, Durham PL. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci. 2006 23 (8 2057 2066.
92. Goadsby PJ. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005 65 (18 2557 2567.
93. Rudolf K, Eberlein W, Engel W, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)- oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl) piperazine: The first CGRP antagonist for clinical trials in acute migraine. J Med Chem. 2005 48 (19 5921 5931.
94. Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J Pain. 2006 7 (1 Suppl 1 S38 47.
95. Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care. 2006 12 (9 Suppl S269 278.
96. Mellar PD. What is new in neuropathic pain? Support Care Cancer.
97. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain. 2000 16 (3 188 192.
98. Melis M, Lobo SL, Ceneviz C, et al. Atypical odontalgia: A review of the literature. Headache. 2003 43 : 1060 1074.
99. Colombo B, Annovazzi POL, Comi G. Therapy of primary headaches: The role of antidepressants. Neurol Sci. 2004 25 (0 s171.
100. Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: Insights into migraine pathophysiology using rizatriptan. Neurology. 2000 55 (9 Suppl 2 S8 14.
101. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci. 1990 600 : 587 598 discussion 598-600.
102. Mikhail GW, Airoldi F, Colombo A. Acute myocardial infarction following the use of antimigraine therapy. J Invasive Cardiol. 2004 16 (10 602 603.
103. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: A randomized blinded crossover study. Headache. 2006 46 (4 642 648.
104. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol. 2005 18 (3 289 292.
105. Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: A role in migraine? Brain. 2005 128 (1 86 97.
106. Schneiderman JH. Topiramate: Pharmacokinetics and pharmacodynamics. Can J Neurol Sci. 1998 25 (3 S3 5.
107. Durham PL, Niemann C, Cady R. Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache. 2006 46 (8 1291 1295.
108. Cohen AS, Goadsby PJ. Paroxysmal hemicrania responding to topiramate. J Neurol Neurosurg Psychiatry. 2007 78 (1 96 97.
109. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006 59 (4 652 661.
110. Bradley DP, Smith MI, Netsiri C, et al. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: Comparison of sumatriptan and tonabersat. Exp Neurol. 2001 172 (2 342 353.
111. Gardell LR, King T, Ossipov MH, et al. Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006 396 (1 44.
112. Zollner C, Stein C. Opioids. Handb Exp Pharmacol. 2007 (177 31 63.
113. Mannino R, Coyne P, Swainey C, Hansen LA, Lyckholm L. Methadone for cancer-related neuropathic pain: A review of the literature. J Opioid Manag. 2006 2 (5 269 276.
114. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache. 2003 43 (s1 16 24.
115. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. J Head Face Pain. 2004 44 (1 35 43.
116. Welch KM. Botulinum toxin type A for the treatment of headache: Con. Headache. 2004 44 (8 831 3.
117. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004 24 (10 838 843.
118. Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache. 2003 43 (s1 25 33.
119. Silberstein SD, Gobel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006 26 (7 790 800.
120. Blumenfeld AM, Dodick DW, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004 22 (2 167 175.
121. Ashkenazi A, Silberstein SD. Headache management for the pain specialist. Reg Anesth Pain Med. 2004 29 (5 462 475.
122. Watkins LR, Maier SF. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003 2 (12 973 985.
123. Clark AR, Dean JL, Saklatvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett. 2003 546 (1 37 44.
124. Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006 12 (11 1269 1277.
125. Waxman SG. Neurobiology: A channel sets the gain on pain. Nature. 2006 444 (7121 831 832.
126. Russell M. Genetics in primary headaches. J Headache Pain. 2007 8 : 190 195.
127. Russell MB, Iselius L, Olesen J. Inheritance of migraine investigated by complex segregation analysis. Hum Genet. 1995 96 (6 726 730.
128. Russell MB, Iselius L, Ostergaard S, Olesen J. Inheritance of chronic tension-type headache investigated by complex segregation analysis. Hum Genet. 1998 102 (2 138 140.
129. Russell MB, Andersson PG, Thomsen LL, Iselius L. Cluster headache is an autosomal dominantly inherited disorder in some families: A complex segregation analysis. J Med Genet. 1995 32 (12 954 956.
130. Ulrich V, Gervil M, Fenger K, Olesen J, Russell MB. The prevalence and characteristics of migraine in twins from the general population. Headache. 1999 39 (3 173 180.
131. Russell MB, Olesen J. Increased familial risk and evidence of genetic factor in migraine. BMJ. 1995 311 (7004 541 544.
132. El Amrani M, Ducros A, Boulan P, et al. Familial cluster headache: a series of 186 index patients. Headache. 2002 42 (10 974 977.
133. Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. Curr Opin Neurol. 2006 19 (3 294 298.
134. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007 13 (1 39 44.
135. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 87 (3 543 552.
136. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003 33 (2 192 196.
137. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005 366 (9483 371 377.
138. Benarroch EE. Neuron-astrocyte interactions: Partnership for normal function and disease in the central nervous system. Mayo Clin Proc. 2005 80 (10 1326 1338.
139. Flores CM, Mogil JS. The pharmacogenetics of analgesia: Toward a genetically-based approach to pain management. Pharmacogenomics. 2001 2 (3 177 194.
140. Rohl T, Kurreck J. RNA interference in pain research. J Neurochem. 2006 99 (2 371 380.
141. Chakraborty C. Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing. Curr Drug Targets. 2007 8 : 469.
142. Prisca H. Behavioral assessment of neuropathic pain in preclinical models. Drug Dev Res. 2006 67 (4 302 307.
143. Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J Neurosci. 1994 14 (5 Pt 1 2708 2723.
144. Vos BP, Hans G, Adriaensen H. Behavioral assessment of facial pain in rats: Face grooming patterns after painful and non-painful sensory disturbances in the territory of the rat's infraorbital nerve. Pain. 1998 76 (1-2 173 178.
145. Imamura Y, Kawamoto H, Nakanishi O. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Exp Brain Res. 1997 116 (1 97 103.
146. Ren K. An improved method for assessing mechanical allodynia in the rat. Physiol Behav. 1999 67 (5 711 716.
147. Scher AI, Stewart WF, Lipton RB. The comorbidity of headache with other pain syndromes. Headache. 2006 46 (9 1416 1423.
148. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006 46 (9 1327 1333.
149. Yunus MB, Arslan S, Aldag JC. Relationship between body mass index and fibromyalgia features. Scand J Rheumatol. 2002 31 (1 27 31.
150. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: A population study. Neurology. 2006 66 (4 545 550.
151. Webb R, Brammah T, Lunt M, Urwin M, Allison T, Symmons D. Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine. 2003 28 (11 1195 1202.
152. Iwasaki Y, Ikeda K. Obesity and migraine: A population study. Neurology. 2007 68 (3 241.
153. Jelinski SE, Magnusson JE, Becker WJ. Factors associated with depression in patients referred to headache specialists. Neurology. 2007 68 (7 489 495.
154. Von Korff M, Resche LL, Dworkin SF. First onset of common pain symptoms: A prospective study of depression as a risk factor. Pain. 1993 55 (2 251.
155. Breslau N, Schultz LR, Stewart WF, Lipton R, Welch KMA. Headache types and panic disorder: Directionality and specificity. Neurology. 2001 56 (3 350 354.
156. Peres MF, Mercante JP, Guendler VZ, et al. Cephalalgiaphobia: A possible specific phobia of illness. J Headache Pain. 2007 8 (1 56 59.
157. Melchart D, Weidenhammer W, Streng A, Hoppe A, Pfaffenrath V, Linde K. Acupuncture for chronic headaches - an epidemiological study. Headache. 2006 46 (4 632 641.